JP2013529600A - 放射の影響を軽減し、及び全身性感染症のリスクを減少させる方法 - Google Patents

放射の影響を軽減し、及び全身性感染症のリスクを減少させる方法 Download PDF

Info

Publication number
JP2013529600A
JP2013529600A JP2013514392A JP2013514392A JP2013529600A JP 2013529600 A JP2013529600 A JP 2013529600A JP 2013514392 A JP2013514392 A JP 2013514392A JP 2013514392 A JP2013514392 A JP 2013514392A JP 2013529600 A JP2013529600 A JP 2013529600A
Authority
JP
Japan
Prior art keywords
gly
asp
ala
peptide derivative
thrombin peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013514392A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013529600A5 (cg-RX-API-DMAC7.html
Inventor
カーニー ダレル
Original Assignee
ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム filed Critical ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム
Publication of JP2013529600A publication Critical patent/JP2013529600A/ja
Publication of JP2013529600A5 publication Critical patent/JP2013529600A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
JP2013514392A 2010-06-11 2011-06-10 放射の影響を軽減し、及び全身性感染症のリスクを減少させる方法 Withdrawn JP2013529600A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35406710P 2010-06-11 2010-06-11
US61/354,067 2010-06-11
PCT/US2011/040006 WO2011156729A2 (en) 2010-06-11 2011-06-10 Methods of mitigating effects of radiation and reducing the risk of systemic infection

Publications (2)

Publication Number Publication Date
JP2013529600A true JP2013529600A (ja) 2013-07-22
JP2013529600A5 JP2013529600A5 (cg-RX-API-DMAC7.html) 2014-07-17

Family

ID=44533067

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013514392A Withdrawn JP2013529600A (ja) 2010-06-11 2011-06-10 放射の影響を軽減し、及び全身性感染症のリスクを減少させる方法

Country Status (5)

Country Link
EP (1) EP2579891A2 (cg-RX-API-DMAC7.html)
JP (1) JP2013529600A (cg-RX-API-DMAC7.html)
AU (1) AU2011265228A1 (cg-RX-API-DMAC7.html)
CA (1) CA2802176A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011156729A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4132948A4 (en) * 2020-04-07 2024-01-03 Chrysalis Biotherapeutics TP5088 ACUTE THERAPY FOR PATIENTS WITH RESPIRATORY VIRUS INFECTION

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352664A (en) 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
WO2004005317A2 (en) 2002-07-02 2004-01-15 The Board Of Regents, The University Of Texas System Thrombin peptide derivative dimers
WO2004014937A2 (en) 2002-07-02 2004-02-19 The Board Of Regents, The University Of Texas System Thrombin peptide derivatives
US7294596B2 (en) 2005-03-14 2007-11-13 Diamorph Ceramic Ab Sintered ceramic material with improved properties and method for its manufacturing
EP2063910A2 (en) * 2006-09-22 2009-06-03 Orthologic Corp. Method of treating endothelial dysfunction
US20100330028A1 (en) * 2007-04-10 2010-12-30 The Board Of Regents The Universityof Texas System Combination therapy for chronic dermal ulcers

Also Published As

Publication number Publication date
CA2802176A1 (en) 2011-12-15
EP2579891A2 (en) 2013-04-17
WO2011156729A2 (en) 2011-12-15
WO2011156729A3 (en) 2012-05-10
AU2011265228A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
TWI257307B (en) Pharmaceutical composition for cardiac tissue repair
EP2875826B1 (en) Composition for preventing or treating sepsis
US7981426B2 (en) Method for stimulating wound healing
CN102892776B (zh) 新型肽及其用途
JP4307561B2 (ja) 創傷の治癒
PT804479E (pt) Método para o tratamento de diabetes mellitus utilizando kgf
KR20050047506A (ko) 섬유소용해성의 금속단백질분해효소를 이용하여유치도관의 폐색을 처리하는 방법
AU2006268091B2 (en) Promotion of epithelial regeneration
JPH04211019A (ja) 創傷治癒促進のためのトロンボスポンデインの使用
ZA200603396B (en) Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
US20130101574A1 (en) Methods of using thrombin peptide derivatives
US20140065119A1 (en) Methods and compositions comprising cyclic analogues of histatin 5 for treating wounds
JP2013529600A (ja) 放射の影響を軽減し、及び全身性感染症のリスクを減少させる方法
CA2304956C (en) Pharmaceutical composition for preventing or treating ischemic diseases
Berlanga Heberprot-P: antecedentes experimentales y bases farmacológicas
US8895502B2 (en) β2-glycoprotein I peptide inhibitors
US10646553B2 (en) Use of recombinant human calcineurin B subunit
CN102485272A (zh) 重组人Prx-6蛋白在治疗烧烫伤方面的用途
US8106009B2 (en) Pharmaceutical composition for preventing or treating ischemic diseases
TWI548415B (zh) 狗圍肛腺瘤之治療方法
CN100484575C (zh) 一类封闭myc细胞增殖途径的染色质肽药物分子
RU2008125169A (ru) Терапевтическое средство для ускоренного заживления кожи, содержащее в качестве активного ингредиента грелин и его производные или вещество, воздействующее на рецептор ghs-r1а
US20030236189A1 (en) Two synthetic peptides for treatment and prevention of cancers
US8361955B2 (en) Methods for treating and preventing brain tumors based on bone morphogenetic proteins
Lee et al. The influence of human serum on the anti-tumour activity of two L-asparaginases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140530

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20150518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150518